Generics· August 20, 2026 · 17 min read
Xcopri's First Generic Settlement: Reading the Cenobamate Patent Fence
By Ran Chen#Generics#Orange Book#Generic Entry
Topic
CNS and Migraine
CNS and migraine drug comparisons, payer restrictions, evidence thresholds, and specialty access workflows.
Deals· August 5, 2026 · 19 min read
Lilly's $3.8B AtaiBeckley deal: big pharma validates psychedelics for TRD
By Ran Chen#M&A#Eli Lilly#Psychedelic Therapy
Specialty· July 30, 2026 · 20 min read
Non-Stimulant ADHD Access Landscape (2026): Simtriyo NDSRI & Generic Economics
Evidence· July 13, 2026 · 16 min read
ADHD Medications in FAERS: 194,052 Adverse-Event Reports by the Numbers
Evidence· July 9, 2026 · 16 min read
Benzodiazepines in FAERS: Adverse Events, Dependence, and Safety Signals
Pipeline· July 1, 2026 · 19 min read
Centanafadine PDUFA July 24, 2026: Pipeline and Access for Otsuka's NDSRI
By Ran Chen#PDUFA Date#Priority Review#CNS and Migraine
Generics· June 26, 2026 · 21 min read
Generic Tecfidera: Dimethyl Fumarate Patent Settlements and NADAC Erosion
By Ran Chen#Generics#Orange Book#PBM
Pricing & Access· May 25, 2026 · 9 min read
CGRP inhibitor access landscape: eight drugs, coverage, and payer criteria in 2026
By Ran Chen#CGRP#CNS and Migraine#Coverage Access